stock upgrade
Jefferies Upgrades GeneDx to Buy
Analysts at the investment bank are confident that GeneDx can achieve its promised 30 percent volume growth for WGS and WES tests in 2025, despite the underwhelming Q1 results.
Wolfe Research Upgrades Danaher to Outperform
The upgrade is based on the firm's improving growth, more reasonable valuations, and its ability to deploy capital.
Barclays Upgrades Revvity to Overweight
The firm's analysts wrote that they see stability in Revvity's diagnostics business and growth above peers in its life sciences and reagents business.
Craig-Hallum Upgrades QuidelOrtho to Buy
The investment bank said the company's core growth should accelerate as QuidelOrtho continues to penetrate the immunoassay market and expand its menu.
Craig-Hallum Upgrades CareDx to Buy
Analyst Bill Bonello said CareDx has substantially de-risked its business and could benefit from Medicare coverage of kidney transplant surveillance testing.